Long Term Nitric Oxide Bioavailability on Vascular Health in Chronic Obstructive Pulmonary Disease

• Status: Completed
• Trial end date: 2018-07-30
• Target enrollment: 0
• Participant gender: All

Summary

Chronic obstructive pulmonary disease (COPD) affects up to 14 million people and is among the top five leading causes of death worldwide. Although COPD is a disease of the lungs, recent evidence indicates that COPD is associated with multiple systemic consequences including vascular endothelial dysfunction. Recently, it has been suggested that more patients with COPD die from cardiovascular disease and coronary heart disease than of direct pulmonary complications. Examination of the mechanisms that contribute to a reduction nitric oxide (NO) bioavailability resulting in vascular endothelial dysfunction in patients with COPD are important as endothelial dysfunction has been indicated to be an independent predictor of future atherosclerotic cardiovascular disease and events.

• Phase: Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Augusta University
• Treatments: Antioxidants; Ascorbic Acid; Nitric Oxide; Thioctic Acid; Verapamil; Vitamin E; Vitamins

Criteria

Inclusion Criteria:

• patients with medically diagnosed COPD

• apparently healthy controls

Exclusion Criteria:

• FEV1/FVC >0.7 (normal lung function in patients only)

• Clinical diagnosis of heart disease or diabetes

• Vasoactive medications (i.e. nitrates, beta-blockers, Viagra etc.)

• uncontrolled high blood pressure

• high blood pressure in your lungs

• thyroid problems

• Fluid in the lungs

• Sleep apnea

• Anemia

• Raynaud's Phenomenon

• GI bleeding

• Gangrene of the digits

• History of low platelets or coagulopathies

• Phenylketonuria (PKU)

• Any allergy to Kuvan